To the full analysis
Haisco Pharmaceutical Group stock: growth
002653.SZHaisco Pharmaceutical Group reported $651.8M in revenue for fiscal 2025, up 16.8% on the prior year, up 5.5% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
15.8%
per year from 2008 to 2025, per share 14.4%
Earnings (Annual rate)
1.7%
per year from 2008 to 2025, per share 0.5%
Free cash flow (Annual rate)
13.1%
per year from 2008 to 2025, per share 11.7%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2008 | |
|---|---|---|---|
| Revenue | 5.5% | 13.6% | 15.8% |
| Revenue per share | 4.5% | 13.0% | 14.4% |
| Earnings | −16.4% | −3.5% | 1.7% |
| Earnings per share | −17.5% | −4.1% | 0.5% |
| Free cash flow | no data | 11.3% | 13.1% |
| Free cash flow per share | no data | 10.7% | 11.7% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2008 | $53.8M | $29.26M | $8.56M |
| 2009 | $72.67M | $42.55M | $51.62M |
| 2010 | $87.22M | $45.85M | $42.95M |
| 2011 | $90.64M | $46.83M | $21.46M |
| 2012 | $120.28M | $66.44M | $50.91M |
| 2013 | $148.82M | $77.86M | $60.65M |
| 2014 | $181.55M | $67.57M | $40.15M |
| 2015 | $181.82M | $55.81M | $23.9M |
| 2016 | $215.29M | $66.4M | $32.67M |
| 2017 | $278.36M | $35.62M | −$217.09K |
| 2018 | $513.88M | $49.97M | $18.09M |
| 2019 | $590.46M | $74.07M | $27.23M |
| 2020 | $499.32M | $95.47M | −$59.31M |
| 2021 | $415.9M | $51.75M | −$100.05M |
| 2022 | $452.19M | $41.55M | −$90.82M |
| 2023 | $503.14M | $44.26M | $8.78M |
| 2024 | $558.07M | $59.3M | $208.62K |
| 2025 | $651.8M | $38.93M | $69.75M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 26 Jun 2026)
- Valuation signal Overvalued since 8 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.